ReviewNeurologia medico-chirurgica2017
The 2016 WHO Classification of Tumours of the Central Nervous System: The Major Points of Revision.
Review in Neurologia medico-chirurgica, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03189420 (Glioma Microenvironment an Exploratory Study), which is not on this map. Cited by 120 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Glioma Microenvironment an Exploratory Study
Who cites it
120 citing papers in PubMed, 2 syntheses or guidelines pooled it, 239 citations in OpenAlex.
- Neuroimaging Biomarkers and Neurocognitive Outcomes in Pediatric Medulloblastoma Patients: a Systematic Review.Cerebellum (London, England) · 2021Pooled it
- Clinical utility of arterial spin labeling for preoperative grading of glioma.Bioscience reports · 2018Pooled it
- PCGF1 Promotes the Tumorigenesis of Malignancies Through Upregulating CCDC34 in Glioma.Annals of clinical and translational neurology · 2026Article
- Multimodal techniques for maximal safe resection of IDH-mutant low-grade glioma involving corpus callosum, a retrospective study and prognosis analysis.Chinese neurosurgical journal · 2026Article
- Berzosertib enhances the sensitivity of pediatric diffuse midline glioma H3K27-altered cells to radiotherapy.Cell death & disease · 2026Article
- Precision oncology in a dish: patient-derived glioma organoids to guide novel therapeutic strategies.Biomarker research · 2026Article
- Differences in regional developmental origins of glioblastomas revealed by integrated molecular profiling.Journal of neuro-oncology · 2026Article
- Two-decade clinicopathological spectrum of gliomas at a tertiary center in LMIC: histological profile and the molecular diagnostic gap.Frontiers in oncology · 2026Article
- Piperidine and valproic acid hybrid compound (F2S4-RSC advances · 2025Article
- Targeting the cuproptosis‑associated gene COL22A1 in glioblastoma using EMD‑1204831 and kaempferol.International journal of oncology · 2025Article
- Potential Biomarkers for IDH-Mutant and IDH-Wild-Type Glioblastomas: A Single-Center Retrospective Study.Journal of clinical medicine · 2025Article
- Pleomorphic xanthoastrocytoma with multiple recurrences and continuous malignant progression to bone metastasis: a case report.Frontiers in surgery · 2025Article
- Glioma Image-Level and Slide-Level Gene Predictor (GLISP) for Molecular Diagnosis and Predicting Genetic Events of Adult Diffuse Glioma.Bioengineering (Basel, Switzerland) · 2024Article
- Adrenal Schwannoma Presenting as an Incidentaloma in a Patient with Uterine Fibroids and Cholelithiasis: a Rare Case Report.Indian journal of surgical oncology · 2024Article
- Review
- Rare Coexistence: Pilocytic Astrocytoma With Atypical Teratoid/Rhabdoid Tumor Features in an Infant.Cureus · 2024Article
- The role of tumor parenchyma and brain cortex signal intensity ratio in differentiating solitary fibrous tumors and meningiomas.Discover oncology · 2024Article
- A Retrospective Genomic Landscape of 661 Young Adult Glioblastomas Diagnosed Using 2016 WHO Guidelines for Central Nervous System Tumors.The oncologist · 2024Article
- Application of Quercetin and its Novel Formulations in the Treatment of Malignancies of Central Nervous System: An Updated Review of Current Evidence based on Molecular Mechanisms.Current medicinal chemistry · 2024Review
- Long-Term Outcomes and Survival Rates of Patients Undergoing Biopsy Vs. Maximum Safe Resection for Thalamic Lesions: A Short Review on Current Evidence.Galen medical journal · 2024Review
60 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The updated 2016 edition of the World Health Organization (WHO) Classification of Tumours of the Central Nervous System (CNS) uses molecular parameters and the histology to define the main tumor categories for the first time. This represents a shift from the traditional principle of using neuropathological diagnoses, which are primarily based on the microscopic features, to using molecularly-oriented diagnoses. Major restructuring was made with regard to diffuse gliomas, medulloblastomas and other embryonal tumors. New entities that are defined by both the histological and molecular features include glioblastoma, isocitrate dehydrogenase (IDH)-wildtype and glioblastoma, IDH-mutant; diffuse midline glioma, H3 K27M-mutant; RELA fusion-positive ependymoma; medulloblastoma, wingless (WNT)-activated and medulloblastoma, sonic hedgehog (SHH)-activated; and embryonal tumor with multilayered rosettes, C19MC-altered. In addition, some entities that are no longer diagnostically relevant-such as CNS-primitive neuroectodermal tumor-have been deleted from this updated edition. The WHO2016 certainly facilitates clinical and basic research to improve the diagnosis of brain tumors and patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.